PAWC
PVLA

P.A.W. Capital’s Palvella Therapeutics PVLA Stock Holding History

P.A.W. Capital’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3,125
Closed -$838K – 70
2019
Q1 		$838K Sell
3,125
-625
-17% -$148K 0.83% 27
2018
Q4 		$798K Buy
3,750
+625
+20% +$194K 1% 25
2018
Q3 		$1.4M Buy
+3,125
New +$1.36M 1.49% 23

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

P.A.W. Capital's PVLA Position: Q2 2019 in Review

P.A.W. Capital sold out of Palvella Therapeutics (PVLA) in Q2 2019, closing a stake of 3,125 shares — an estimated $838K sold.

P.A.W. Capital first reported a position in PVLA in Q3 2018 and held it in 3 quarters. The position peaked at $1.4M in Q3 2018. 93 funds tracked by Wall St. Rank hold PVLA as of Q2 2019.

  • P.A.W. Capital reported no remaining Palvella Therapeutics position as of Q2 2019 after selling out during the quarter.
  • P.A.W. Capital sold 3,125 Palvella Therapeutics shares in Q2 2019, an estimated $838K.
  • P.A.W. Capital first reported a position in Palvella Therapeutics in Q3 2018 and held it in 3 quarters.
  • P.A.W. Capital's Palvella Therapeutics position peaked at $1.4M in Q3 2018.
  • 93 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2019.

Based on P.A.W. Capital's 13F filing for Q2 2019, filed 31 Jul 2019.